Low expression of WW domain-containing oxidoreductase associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection.
Low expression of WW domain-containing oxidoreductase associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection.
复制标题
含WW结构域的氧化还原酶的低表达与肝细胞癌的侵袭性和治愈性切除后的复发相关
DOI:
10.1002/cam4.1591
复制
发表时间:
2018-07
期刊:
影响因子:
4
通讯作者:
Ren N
中科院分区:
文献类型:
--
作者:
Zhou C;Chen W;Sun J;Atyah M;Yin Y;Zhang W;Guo L;Ye Q;Dong Q;Shi Y;Ren N
WW domain‐containing oxidoreductase (WWOX), which has a protein‐interaction domain and is regarded to be a tumor suppressor, has been known to play an important role in anti‐angiogenesis and cancer progression. This study aimed to investigate prognostic values of WWOX expression in hepatocellular carcinoma (HCC) patients after hepatectomy. Additionally, we intended to formulate a valuable prognostic nomogram for HCCs. 182 HCC patients who underwent hepatectomy from January 2009 to January 2010 were enrolled in our study. qRT‐PCR, Western blot, and immunohistochemistry on tissue microarrays were then used to determine the expression levels of WWOX. An evaluation of the role of WWOX expression levels in the prognosis and outcome of patients was established. A decrease in the expression of WWOX was found when compared to adjacent tumor‐free tissues, which led to worse overall survival (OS) and recurrence‐free survival (RFS) and, therefore, was considered as an independent negative factor in the prognosis of HCC. Two nomograms, comprising WWOX, alpha‐fetoprotein (AFP), tumor size, and γ‐glutamyltransferase (γ‐GT), were constructed to obtain superior discriminatory abilities than conventional staging systems in terms of C‐index and clinical net benefit on decision curve analysis (DCA) for OS and RFS. Our data suggest that WWOX expression is strongly related to HCC post‐resection aggressiveness and recurrence. Additional advanced and accurate predictive model through the incorporation of WWOX into nomogram could help predict OS or RFS for HCC patients.
登录
查看更多内容
影响因子:
3.7
作者:
Lee HL;Cheng HL;Liu YF;Chou MC;Yang SF;Chou YE
通讯作者:
Chou YE
影响因子:
3.5
作者:
Ried, K;Finnis, M;Richards, RI
通讯作者:
Richards, RI
影响因子:
158.5
作者:
Llovet, Josep M.;Ricci, Sergio;Bruix, Jordi
通讯作者:
Bruix, Jordi
影响因子:
4
作者:
Mignot, Cyril;Lambert, Laetitia;Philippe, Christophe
通讯作者:
Philippe, Christophe
DOI:
10.1016/s1470-2045(14)71116-7
发表时间:
2015-04
期刊:
The Lancet. Oncology
影响因子:
--
作者:
Balachandran VP;Gonen M;Smith JJ;DeMatteo RP
通讯作者:
DeMatteo RP